iPS cell-derived natural killer cell therapy / iCamuno Biotherapeutics - LARVOL DELTA

Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer (PRNewswire) - "I Peace...and iCamuno Biotherapeutics...announced a significant milestone with the dosing of the first patient in a clinical trial using iPS cell-derived natural killer (iNK) cells for ovarian cancer immunotherapy. iCamuno will lead the trial, which will test the safety and efficacy of NK cells made from I Peace's cGMP-compliant iPS cells using iCamuno's NK cell differentiation technology...This trial leverages iCamuno's abilities to create cGMP-grade iPS cell-derived NK cells with improved consistency and effector function. The initial phase will focus on ovarian cancer, with potential expansion to a broader range of diseases."

Trial status • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor